BioPharma Resources

Drug Trial Radar · NCT07412756

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD 1)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Feb 9, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period with a potential post treatment period that combined will last a minimum of 12 months, and the follow up period that will last approximately 2 months.

Conditions

  • Depressive Disorder, Major

Interventions

  • BrenipatideDrug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Relapse Defined as the Number of Days from Randomization to Date on Which the Participant Meets Any Relapse Criterion of Major Depressive Disorder (MDD)Time frame: From Randomization in Double-Blind Adjunctive Treatment to First Relapse For at Least 12 Months

Locations

180 sites in 15 countries. Site status is shown where the registry gives one.

  • Accellacare - Moorpark

    Moorpark, California · Recruiting

  • ATP Clinical Research

    Orange, California · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Encore Medical Research

    Hollywood, Florida · Recruiting

  • K2 Medical Research - Maitland

    Maitland, Florida · Recruiting

  • Life Medical Research Group Corp

    Miami Gardens, Florida · Recruiting

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida · Recruiting

  • CLA Research

    Naples, Florida · Recruiting

  • Optimal Research Sites

    Orange City, Florida · Recruiting

  • Charter Research - Orlando

    Orlando, Florida · Recruiting

  • K2 Medical Research - Tampa

    Tampa, Florida · Recruiting

  • CenExel iResearch, LLC

    Decatur, Georgia · Recruiting

  • Indiana University Health Neuroscience Center

    Indianapolis, Indiana · Recruiting

  • Cedar Valley Medical Specialists

    Waterloo, Iowa · Not yet recruiting

  • Pharmasite Research, Inc.

    Baltimore, Maryland · Recruiting

  • Adams Clinical Boston

    Boston, Massachusetts · Recruiting

  • K2 Medical Research - Foxborough

    Foxborough, Massachusetts · Recruiting

  • Adams Clinical Watertown

    Watertown, Massachusetts · Recruiting

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan · Recruiting

  • Arch Clinical Trials

    St Louis, Missouri · Recruiting

  • Vector Clinical Trials

    Las Vegas, Nevada · Recruiting

  • Adams Clinical Harlem

    New York, New York · Recruiting

  • Summit Headlands

    Portland, Oregon · Recruiting

  • Penn Medicine: University of Pennsylvania Health System

    Philadelphia, Pennsylvania · Recruiting

  • Suburban Research Associates

    West Chester, Pennsylvania · Recruiting

  • Circle Clinical Research

    Sioux Falls, South Dakota · Recruiting

  • Adams Clinical Dallas

    DeSoto, Texas · Recruiting

  • Re:Cognition Health - Fort Worth

    Fort Worth, Texas · Recruiting

  • Consano Clinical Research, LLC

    Shavano Park, Texas · Suspended

  • Alpine Research Organization

    Clinton, Utah · Recruiting

  • Re:Cognition Health

    Fairfax, Virginia · Recruiting

  • Northwest Clinical Research Center

    Bellevue, Washington · Recruiting

  • NeuroCentrix

    Carlton, Australia · Recruiting

  • Lyell McEwin Hospital

    Elizabeth Vale, Australia · Not yet recruiting

  • Barwon Health

    Geelong, Australia · Recruiting

  • Multidisciplinary Alfred Psychiatry Research Centre

    Melbourne, Australia · Recruiting

  • Paratus Clinical Research - Melbourne

    Northcote, Australia · Recruiting

  • Toowoomba Hospital

    Toowoomba, Australia · Recruiting

  • Westmead Hospital

    Westmead, Australia · Recruiting

  • Hospital das Clínicas da UFMG

    Belo Horizonte, Brazil · Recruiting

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.